Login
Navigate Fool.com
Will AGEN beat
the market?

Agenus, Inc.

NASDAQ: AGEN

Community Rating: 2 Stars: Unattractive

2.55 0.14 (5.81%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $2.43
Previous Close $2.41
Daily Range $2.37 - $2.57
52-Week Range $2.27 - $5.40
Market Cap $158.5M
P/E Ratio -2.28
Dividend (Yield) $0.00 (0.0%)
Volume 386,865
Average Daily Volume 953,874
Current FY EPS -$0.68

How do you think AGEN
will perform against the market?

Top AGEN Bull/Bear Pitches

 

zzlangerhans (< 20)
Submitted May 6, 2011

0.9 has been a relatively stable floor for Agenus over the last eight months. Potential positive catalysts include presentation of data from phase II trial of Prophage G-200 in glioma and results of s … More

0 Replies Reply Report this Post
 

Ernbo6 (< 20)
Submitted May 15, 2007

Antigenics Inc. is a biotechnology company developing technologies and products to treat cancers, infectious diseases and autoimmune disorders, primarily based on immunological approaches. Its advance … More

1 Replies Reply Report this Post

News & Commentary

The Worst Biotech Failures of the Week

See which companies suffered the worst clinical setbacks in the week ending April 4.

Is Biotech in a Bubble? The Bear Case Explained

Biotech IPOs provide some powerful indications...

Today’s Top Biotech Stories: MannKind, GSK, Myriad, and Alnylam

MannKind, GlaxoSmithKline, Myriad Genetics, and Alnylam Pharmaceuticals could all make waves in the biotech sector this morning.

Sector Update: Healthcare Shares Higher Pre-Market; Agenus Sinks 9% As GlaxcoSmithKline Halts Study

Sector Update: Healthcare

The Week's Worst Clinical Failures

See which companies suffered the worst clinical setbacks last week.

This Week in Biotech: Endocyte Doubles, Intercept Wobbles, and Geron Gets Smacked Again

Two regulatory actions, four mammoth clinical study updates, and an intriguing immunotherapeutic collaboration, are this week's most important biotech stories.

Why Agenus Inc. Shares Tumbled

Agenus shares are rocked after a collaborative phase 3 trial fails to meet its co-primary first and second endpoints. Find out why this may not be the end of the world for Agenus shareholders.

Morning Movers in Biotech: Agenus Inc., GlaxoSmithKline plc and Synta Pharmaceuticals Corp.

Today's top stories in biotech and health care.

Today’s Top Biotech Stories: Xoma, Biogen, Agenus, and GSK

Xoma, Biogen, Agenus, and GSK could all loom large in health care headlines this morning.

See More AGEN News...

Sector

Healthcare

Industry

Drugs

Agenus, Inc. (AGEN) Description

A biotechnology company, developing technologies and products to treat cancers and infectious diseases, based on immunological approaches. Website: http://www.antigenics.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks